Previous 10 | Next 10 |
Krystal Biotech (NASDAQ:KRYS) said it submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its gene therapy B-VEC to treat patients with dystrophic epidermolysis bullosa (DEB). DEB is a rare disease in which the skin becomes fragile and can tear or blist...
PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking appr...
PITTSBURGH, June 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldman Sachs 43 rd Annual Global Healthcare Conference in Rancho Palo...
In a bear market, Krystal still shows that strong execution can be lucrative. They will file a BLA this quarter. The market potential is huge. For further details see: Krystal Biotech: High Potential, Buy-At-Dips Stock
PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), a...
Krystal Biotech press release (NASDAQ:KRYS): Q1 GAAP EPS of -$1.99 misses by $0.93. Cash, cash equivalents, and investments totaled $468M on March 31, 2022. “Our primary objective in 2022 is to prepare for the potential approval and launch of B-VEC in the U.S.” said Krish S...
Biologics License Application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022 FDA allows dosing at a patient’s home in the Open Label Extension Study of B-VEC for the treatment of DEB Positive Cli...
PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill...
April 28, 2022 Download PDF PITTSBURGH, April 28, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune Aesthetics”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced the formation and members...
PITTSBURGH, April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extens...
News, Short Squeeze, Breakout and More Instantly...
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U....
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...